Precision medicine has come a long way towards benefiting patient outcomes and enhancing research tools. In recent years, the integration of multi-scale omics from genomic, proteomic, and transcriptomic foundations has impacted how biological pathways and disease progression are studied. The industry has rapidly progressed due to both improved, ultra-sensitive technologies and increased awareness across expert domains, exponentially advancing innovative approaches to come within reach. Increasing access to both patient and population data provides additional layers of understanding. Reveal and QuantumCyte are now partnering to offer this combination of advanced multi-omic technologies as a tool for oncology research.
Reveal Biosciences is a San Diego-based computational pathology company, developing Artificial Intelligence (AI)-driven tools that provide quantitative outcomes. Our technology uses layered deep-learning platforms and real data learning sets to build algorithms to help pathologists and researchers assess and quantify disease. Our recent partnership with QuantumCyte Inc., a pioneer in spatial genomics, addresses a critical unmet need for advanced tools to expedite multi-scale data analysis to facilitate improved understanding of oncology. Combining our approaches to AI, pathology, and genomics, this collaboration allows for multiple layers of quantitative analysis through a multi-omics data bundle (MOD-B) approach.
Tissue microarrays (TMAs) allow for high-throughput analysis of hundreds of patient tissue samples simultaneously. Reveal Biosciences offers a broad range of human cancer TMAs including breast, colon, prostate, and more. Each TMA slide is cut fresh to order to maximize the preservation and extraction of nucleic acids. In addition to the clinical data available for each tissue core, we offer quantitative immunohistochemistry (IHC) to visualize protein expression on a cell-by-cell basis. Our AI-based tumor profiling workflow provides an additional layer of quantitative data for tumor, stroma, inflammatory, and necrotic regions.
QuantumCyte has pioneered Q1, a unique platform that rapidly automates nucleic acid preparation and workflows directly in regions of interest, such as TMA cores. Nucleic acid sample prep includes transcriptome, or targeted gene amplification. MOD-B uses QuantumCyte’s Q1 reagent delivery product and nucleic acid preparation on TMAs of interest to generate the genomic data component within the data bundle.
Taken together, the Multi-Omics Data Bundle (MOD-B) provides novel integrated data analysis and visualization technology that holds significant potential for target validation or preclinical oncology research. Contact us at [email protected] to speak with our scientific team and learn more about how this technology could benefit your research.